Literature DB >> 3382594

Cimetidine does not increase alpha 1-acid glycoprotein serum concentrations.

R C Parish1, V P Gotz, J L Mehta.   

Abstract

Serum concentrations of alpha 1-acid glycoprotein (AAG) were studied in six healthy, male volunteers before and after administration of cimetidine, 300 mg by mouth every 6 h for 2 days. Serum AAG concentrations were measured at three different times during the first day, i.e. before cimetidine administration, and on the fourth and sixth days, after commencing cimetidine administration. Neither cimetidine treatment nor time of day contributed significantly to differences in serum AAG concentration, and no interaction of these factors was observed. It is concluded that altered drug-AAG binding as a result of cimetidine therapy is not likely to be an important mechanism contributing to cimetidine drug interactions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3382594      PMCID: PMC1387815          DOI: 10.1111/j.1365-2125.1988.tb03337.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Acute phase protein response to infection in elderly patients.

Authors:  R A Kenny; H M Hodkinson; M L Cox; D Caspi; M B Pepys
Journal:  Age Ageing       Date:  1984-03       Impact factor: 10.668

2.  Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.

Authors:  D W Holt; A M Hayler; G F Healey
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

3.  Increase of alpha 1-acid glycoprotein after treatment with amitriptyline.

Authors:  P Baumann; D Tinguely; J Schöpf
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

4.  Alteration in plasma proteins and platelet functions with aging and cigarette smoking in healthy men.

Authors:  F C Chao; J L Tullis; C A Alper; R J Glynn; J E Silbert
Journal:  Thromb Haemost       Date:  1982-06-28       Impact factor: 5.249

5.  Lidocaine plasma protein binding.

Authors:  P A Routledge; A Barchowsky; T D Bjornsson; B B Kitchell; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

6.  Complement components, complement activation, and acute phase response in systemic lupus erythematosus.

Authors:  G Sturfelt; A G Sjöholm
Journal:  Int Arch Allergy Appl Immunol       Date:  1984

7.  Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine.

Authors:  R C Parish; V P Gotz; L M Lopez; J L Mehta; S H Curry
Journal:  Ther Drug Monit       Date:  1987-09       Impact factor: 3.681

8.  alpha 1-acid glycoprotein involvement in high affinity binding of tricyclic antidepressants to human plasma.

Authors:  J I Javaid; K Hendricks; J M Davis
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

9.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

10.  Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy.

Authors:  F X McGowan; M J Reiter; E L Pritchett; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.